Fabio Guolo

1.4k total citations
46 papers, 306 citations indexed

About

Fabio Guolo is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Fabio Guolo has authored 46 papers receiving a total of 306 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hematology, 14 papers in Public Health, Environmental and Occupational Health and 13 papers in Genetics. Recurrent topics in Fabio Guolo's work include Acute Myeloid Leukemia Research (23 papers), Acute Lymphoblastic Leukemia research (14 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Fabio Guolo is often cited by papers focused on Acute Myeloid Leukemia Research (23 papers), Acute Lymphoblastic Leukemia research (14 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Fabio Guolo collaborates with scholars based in Italy, United States and Switzerland. Fabio Guolo's co-authors include Paola Minetto, Roberto M. Lemoli, Emanuela Marcenaro, Marco Greppi, Marco Gobbi, Silvia Pesce, Valentina Obino, Marino Clavio, Maurizio Miglino and Filippo Ballerini and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Scientific Reports.

In The Last Decade

Fabio Guolo

42 papers receiving 303 citations

Peers

Countries citing papers authored by Fabio Guolo

Since Specialization

Citations

This map shows the geographic impact of Fabio Guolo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabio Guolo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabio Guolo more than expected).

Fields of papers citing papers by Fabio Guolo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabio Guolo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabio Guolo. The network helps show where Fabio Guolo may publish in the future.

Co-authorship network of co-authors of Fabio Guolo

This figure shows the co-authorship network connecting the top 25 collaborators of Fabio Guolo. A scholar is included among the top collaborators of Fabio Guolo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabio Guolo. Fabio Guolo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	The protective role of HCWs communication for the distress of newly diagnosed people with leukemia and lymphoma	PEC Innovation	Fabio Guolo, Francesca Riccardi et al.	0
2	Tyrosine kinase inhibitor discontinuation in non-allografted Philadelphia-positive acute lymphoblastic leukemia patients: a Campus ALL real-life study	Haematologica	Michela Ansuinelli, Cristina Papayannidis et al.	2
3	Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis	Scientific Reports	Debora Soncini, Concetta Conticello et al.	2
4	Harnessing Immune Response in Acute Myeloid Leukemia	Journal of Clinical Medicine	Paola Minetto, Marco Greppi et al.	8
5	Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire	Frontiers in Immunology	Raffaella Meazza, Loredana Ruggeri et al.	7
6	P523: THE COMPARISON OF VFLAI, FLAI AND 3 + 7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD	HemaSphere	Alfonso Piciocchi, Giovanni Marconi et al.	1
7	Blastic plasmocitoid dendritic cell neoplasm with leukemic spread: a GIMEMA survey	Blood Advances	Caterina Giovanna Valentini, Alfonso Piciocchi et al.	9
8	Prognostic Impact of Minimal Residual Disease Assessment in Elderly Patients with Secondary Acute Myeloid Leukemia. a Comparison between CPX-351 and Intensified Fludarabine-Based Regimens	Blood	Fabio Guolo, Paola Minetto et al.	1
9	Harnessing NK Cells for Cancer Treatment	Frontiers in Immunology	Paola Minetto, Fabio Guolo et al.	63
10	A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia	Leukemia Research	R Marcolin, Fabio Guolo et al.	9
11	Patient and Therapy-Related Factors Affecting the Toxicity of Pegylated-Asparaginase for the Treatment of Adult Acute Lymphoblastic Leukemia	Blood	Paola Minetto, Fabio Guolo et al.	3
12	Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors	Blood	Paola Minetto, Debora Soncini et al.	1
13	Good tolerability of high dose colistin-based therapy in patients with haematological malignancies	Infection	Paola Tatarelli, Fabio Guolo et al.	3
14	Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes	Leukemia Research	Paola Minetto, Fabio Guolo et al.	11
15	Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia	Annals of Hematology	Marino Clavio, Anna Maria Raiola et al.	15
16	Bloodstream Infections Are an Improbable Cause of Positive Serum (1,3)-β-d-Glucan in Hematology Patients	Clinical and Vaccine Immunology	Elisa Furfaro, Małgorzata Mikulska et al.	12
17	Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia	Leukemia Research	Marino Clavio, Raffaella Grasso et al.	27
18	Management of Early Stage Chronic Myeloid Leukemia: State-of-the-art Approach and Future Perspectives	Current Cancer Drug Targets	Federica Galaverna, Chiara Ghiggi et al.	2
19	De novo AML patients with favourable–intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened “GO question”	Annals of Hematology	Marino Clavio, Fabio Cruciani et al.	3
20	Nucleophosmin gene-based monitoring inde novocytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression	Leukemia & lymphoma	Maurizio Miglino, Nicoletta Colombo et al.	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact